In its latest bulletin, Abbott India has revealed that it has voluntarily recalled a particular batch of Thyronorm tablets due to mislabeling in Madhya Pradesh and Telangana states.
Posted on – Wed 26 Apr 23 at 03:31pm
representative image
Hyderabad: Abbott India Ltd has issued an announcement to draw public attention that it has voluntarily recalled a particular batch of Thyronorm tablets due to mislabeling in Madhya Pradesh and Telangana states.
“The recall of Thyronorm, a drug commonly used to treat hypothyroidism, was initiated due to mislabeling of a small number of bottles from a particular batch that were mislabeled as a 25 mcg dosage strength, which contained 88 mcg of Pills,” the notice said.
The affected Thyronorm batch number is AEJ0713 and was produced in March 2023. In the notice, Abbott said only a small number of vials in the batch were mislabeled at 25mcg instead of the intended dose of 88mcg.
Emphasizing the importance of taking the correct dosage, the company is voluntarily recalling mislabeled batches. Abbott said there were no quality issues with the product and it has not received any reports of adverse effects on patients. The company is working closely with distributors and partners to facilitate the recall process.
Mislabeled Thyronorm batches are only invoiced in Madhya Pradesh and Telangana and will not affect any other batches or dosage strengths of Thyronorm or other Abbott products. The company urges anyone who may have purchased this batch of Thyronorm to contact their healthcare provider and return the product for a refund.
